Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
Part of paid clinical trials in La Jolla, California.
- Sponsor
- University of California, San Diego
- Study ID
- NCT06665971
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Eosinophilic Esophagitis (EoE)
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] — DRUGDosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
Study Details
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE have dysfunction of the muscle of the esophagus (impaired peristalsis) that is not favorable for the transport function. Main question this study aims to answer is: Whether Dupilumab helps improve muscle activity of the esophagus in participants with EOE? Participants will: Take Dupilumab every week for 12 weeks. Visit the clinic before and after starting the medication. Keep a diary of symptoms.
Key Dates
- Start date
- Nov 10, 2024
- Status verified
- Oct 2024
- Primary completion
- Sep 15, 2026
- Completion
- Nov 14, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: EoE participants treated with DupilumabAll the participants will be treated with once a week subcutaneous injection of Dupilumab 300 mg through for 12 weeks. There is no placebo arm in the study.
Primary Outcome Measure
To determine the change in the peak esophageal muscle thickness during peristalsis following 12 weeks of Dupilumab [ Time Frame: From baseline assesment at 2 weeks to the end of the study at 14 weeks ]
Central Contacts
- Anant Gupta, MBBS314-685-9214
- Ravinder Mittal, MD858-534-3328
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California San Diego (UCSD) Health Medical center | La Jolla | California | 92037 |
Find similar trials in La Jolla, CA
Related Studies
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of CareRecruiting · Regeneron Pharmaceuticals · Phoenix, Arizona
- Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral ImmunotherapyRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisPHASE3 · Recruiting · Regeneron Pharmaceuticals · Phoenix, Arizona
- Surface EMG Testing on Swallowing in EoE PatientsRecruiting · Mayo Clinic · Rochester, Minnesota